A Phase 2, Multi-center study evaluating the safety and efficacy of ENV-101 (Taladegib) in subjects with Idiopathic Pulmonary Fibrosis (IPF)

  • Li, Xun (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description


Short titleENV-IPF-101
StatusActive
Effective start/end date20/07/2119/07/26

Keywords

  • phase 2 study
  • treatment safety
  • treatment efficacy
  • pulmonary fibrosis